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To the Editor-in-Chief: 
Since the onset of COVID-19 in December 2019, 
millions of people have been infected with SARS-
CoV-2 across the world and many have died of the 
disease (1). Therefore, the search for any drug 
with a positive effect on the course of this disease 
is of great value. Fampridine is a drug widely used 
to improve gait disorders in patients with multiple 
sclerosis (2). The mentioned drug is a potassium 
channel blocker that increases the conduction of 
action potentials in damaged axons (3). However, 
it is not evident whether this drug can affect 
potassium channels on the surface of other cells. 
Some studies have revealed that potassium-
blocking drugs can play a role in reducing the 
incidence or severity of infectious diseases (4-6). 
Hence, the question of whether fampridine could 
also have a protective effect on patients with MS in 
the face of COVID-19 should be attended to. The 
incidence and severity of COVID-19 in patients 
with multiple sclerosis (MS) receiving fampridine 
(Dalfyra®, Arvand Pharmed) were evaluated to 
address the mentioned question. 
In the present study conducted in November 
2020, 117 MS patients receiving fampridine were 
tested for COVID-19. The majority of these 
patients (55.6%) were receiving rituximab (Table 
1). Of these 117 patients, nine were infected by 
the COVID-19 virus. Of these nine patients, five 
and four were female and male, respectively. Eight 
of the infected patients took rituximab, and one 
did not take any disease modulatory drug (DMD). 
One of these nine patients required to be 
hospitalized (Table 2). She was a 40-year-old 
woman with MS disease duration of 3.5 years and 
was treated with rituximab. Her symptoms were 
manifested by fever, shortness of breath, and dry 
cough. The mentioned patient was hospitalized for 
three days due to the conditions associated with 
COVID-19. She did not need to be admitted to the 
intensive care unit (ICU) and was discharged with 
a good medical condition after three days. 
The incidence of COVID-19 in these patients was 
7%, and the hospitalization rate was 11% in 
patients receiving fampridine. None of the 
patients with COVID-19 required hospitalization 
in the ICU, and no fatalities were reported. 
In a previous study conducted on 4,647 patients 
with MS in Iran, the incidence rate was reported to 
be 1.46% during the first wave of COVID-19 (May 
2020) (7). The incidence rate in our study was 7%, 
which was significantly higher than the 
Table 1: The type of used medications 
Type of drug Number (%) 
Rituximab  65 (55.6) 
Fingolimod 8 (6.8) 
Glatiramer Acetate 4 (3.4) 
Interferon β-1a 3 (2.6) 
Ocrelizumab 2 (1.7) 
Azathioprine 2 (1.7) 
Cladribine (IV) 2 (1.7) 
Interferon β-1b 1 (0.9) 
IVIG 1 (0.9) 
Mycophenolate mofetil 1 (0.9) 
No medication 28 (23.9) 
IV: intravenous; IVIG: intravenous immunoglobulin 
 
 
Table 2: The demographic characteristics of the patients  
COVID-19 Infection Yes No 
N (%) 9 (7.69) 108 (92.31) 
Sex Male Female Male Female 
N (%) 4 (44.44) 5 (55.56) 29 (26.85) 79 (73.15) 
Age, years (SD) 44.99±8.15 44.28±8.77 40.83±9.80 44.52±9.19 
Duration of disease, years (SD) 5.31±2.49 9.00±8.50 10.66±7.97 10.48±6.56 
Duration of Fampridine Medication use, years (SD) 3.75±2.22 3.16±1.00 2.24±1.51 2.54±1.58 
N: number; SD: standard deviation 
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percentage of the previous report. It should be 
noted that our study was conducted at the height 
of the second wave of COVID-19 in Iran, during 
which a much larger number of people were 
infected with COVID-19, according to official 
statistics (8).  
In the previous study, the hospitalization rate was 
25%. However, fampridine users, despite being 
more infected, had a lower hospitalization rate 
(11%), which indicated a lower severity of the 
disease in these patients. The mentioned finding 
could be due to the possible protective effect of 
fampridine on the exacerbation of COVID-19 in 
these patients. 
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